The TransAeris™ System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
- Minimize mechanical ventilation exposure
- Enhance ability to wean from mechanical ventilation
- Temporary stimulation up to 30 days
The PARADIGM Trial
A New U.S. Medical Device Trial Assessing the Use of NeuRx® Diaphragm
Pacing System (DPS) With NIV (e.g. BiPAP, Trilogy®, etc.) In Patients With ALS.
For more information about the study or for a participating study site near
you, please contact Synapse Biomedical, Inc.
Call toll free 1.888.767.3770 or email firstname.lastname@example.org
Only FDA device specifically approved for ALS patients
For patients with ALS, the FDA approved NeuRx DPS® delays the need for mechanical ventilation and tracheostomy. It has also been shown to help condition the diaphragm muscle to improve fatigue resistance.
Our breakthrough diaphragm pacing system for spinal cord injuries
Our FDA approved NeuRx DPS® is specifically designed to decrease the reliance on mechanical ventilators for patients with spinal cord injuries.